AbbVie Grows Gastrointestinal Business With Rinvoq Approval In UC

 
• By Joseph Haas

Along with Skyrizi’s expected approval in Crohn’s, AbbVie says Rinvoq in ulcerative colitis is key to its Humira sales erosion strategy. It is Rinvoq’s third US supplemental approval since December.

AbbVie building
AbbVie gets third supplemental FDA approval for Rinvoq in four months • Source: Alamy

More from New Products

More from Scrip